MediGene sells rosacea drug rights to Galderma
This article was originally published in Scrip
Executive Summary
MediGenehas sold the European rights to its rosacea treatment, Oracea (doxycycline), to the dermatological companyGalderma, just days after the European Commissiongave the all-clear to the product's approval in EU countries. The sale is part of MediGene's plan to move out of the dermatological arena and focus on cancer and immunology.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.